Infection Prevention Solutions: From Concept to Scalable Manufacturing

Hospital Acquired Infections (HAIs), including Surgical Site Infections (SSIs), Central Line-Associated Bloodstream Infections (CLABSI), and Ventilator-Associated Pneumonia (VAP), represent one of the most consequential challenges in modern healthcare delivery. Demand for single-use medical devices and components engineered to reduce HAI risk continues to grow, and OEMs in this space need more than a supplier. They need a manufacturing partner with the engineering depth to co-develop products, the materials expertise to match the right films, foams, fabrics, and other specialty materials to application specific requirements, and the production infrastructure to scale with quality and consistency.

UFP MedTech is a contract development and manufacturing organization (CDMO) with ISO 13485 certified and FDA registered facilities. We work with OEMs across the full product lifecycle from initial concept through high-volume production. Whether you are developing a single-use protective assembly or a complex fluid management system, UFP MedTech provides the technical capability and compliance framework to bring infection prevention products to market efficiently and at scale.

What Are Infection Prevention Solutions in Medical Device Manufacturing?

Infection prevention, in a medical device context, is an umbrella term covering products and systems designed to interrupt pathogen transmission pathways between patient, clinician, equipment, and environment. The primary clinical categories driving demand for these products are Hospital Acquired Infections (HAIs):

• Surgical Site Infections (SSI): infections occurring at or near a surgical incision. UFP MedTech products in this category include surgical robot drapes and equipment covers, and surgical prep applicators (e.g. CHG and iodine).
• Central Line-Associated Bloodstream Infections (CLABSI): bloodstream infections linked to central venous catheter access. Relevant products include disinfecting caps, IV port cleaners, and other precision foam components used in devices designed to support disinfection protocols.
• Ventilator-Associated Pneumonia (VAP): pneumonia in patients on mechanical ventilation. Relevant products include ventilator circuit components, foam-tipped oral swabs, and fluid management components.

Materials feed into all of these application categories. Reticulated polyurethane foam, for example, is commonly used in CHG and iodine surgical prep applicators, disinfecting caps, IV port cleaners, and oral swabs where controlled fluid uptake, retention, and release are important. TPU is used in wound care, urinary applications, and sterile packaging designed to reduce surgical site contamination. Non-wovens and fabrics are used across UTI-related and procedural drape constructions.

What determines whether a product performs its infection prevention function is not just its form, it is the material selection, the construction method, and the precision of manufacture. Getting those variables right from the design stage is where a capable CDMO partner makes the difference.

Key Design Considerations for Infection Prevention Products

Infection prevention performance must be engineered in. It cannot be added after the fact. OEM engineers working on these products need to address the following design parameters from the outset:

• Biocompatibility: all materials in patient or clinician contact must comply with ISO 10993. Material selection at the design stage drives biocompatibility compliance. Testing confirms it, but material choice determines it.
• Sterilization Compatibility: the product and all its materials must survive the chosen sterilization method (EtO, gamma, e-beam) without loss of barrier performance, dimensional integrity, or surface properties.
• Fluid Management: for fluid-handling assemblies (drainage systems, wound exudate management), flow path design, seal integrity, and leak resistance are critical. These must be validated through testing, not assumed from material datasheets.
• Assembly and Ease of Use: products intended for use in sterile field environments or under time pressure must be designed for intuitive deployment. Errors in product application can negate barrier performance. Design for assembly efficiency is as important as material selection.

UFP MedTech’s design engineering team works alongside OEM engineers at concept stage to pressure-test these parameters before tooling investment is made.

Materials Used in Infection Prevention Medical Devices

Material selection is the single most consequential design decision for infection prevention products. The core materials used in this category and their primary applications are outlined below.

UFP MedTech maintains an extensive library of qualified medical-grade materials across films, foams, and non-wovens. Material selection is guided by the product’s regulatory classification, intended sterilization method, and performance specification, not by availability alone.

Cleanroom and Contamination Control Requirements

Many infection prevention products require manufacturing in a controlled environment, an obvious necessity given these are products designed to prevent the very contamination they would introduce if improperly manufactured. Cleanroom classification under ISO 14644 establishes permissible airborne particulate concentrations. ISO Class 7 and Class 8 environments are common requirements for single-use medical device manufacturing.

UFP MedTech’s cleanroom manufacturing capabilities are available at every stage, from prototype builds through full-volume production runs, with the documentation required to support OEM regulatory submissions.

Understanding FDA QMSR and ISO 13485 Requirements for OEMs

Two regulatory frameworks govern the manufacturing of infection prevention medical devices in the US market, and understanding how they interact is essential for OEMs selecting a CDMO partner.

ISO 13485 is the international quality management system standard for medical device manufacturers. Certification requires documented processes, rigorous supplier controls, and a quality system built around risk management. Since ISO 13485 certification is site-specific, it is important to confirm which facilities hold certification and what the scope covers. UFP MedTech has ISO 13485 certified and FDA registered facilities aligned with ISO 13485 and applicable FDA Quality Management System Regulation (QMSR / 21 CFR Part 820) requirements. For OEMs, this means traceability is embedded in every production batch, a critical requirement when devices enter regulated markets.

The FDA Quality Management System Regulation (QMSR), codified as 21 CFR Part 820, sets equivalent requirements for US-market devices and has been updated to align more closely with ISO 13485. The regulation covers design controls, purchasing controls, production and process controls, and corrective/preventive action (CAPA). A manufacturing non-conformance is a regulatory event, regardless of where in the supply chain it occurs. OEMs are accountable for the quality systems of the partners they choose.

For infection prevention products specifically, validation requirements are significant. Process validation (IQ/OQ/PQ), sterilization validation, and packaging integrity testing are all required before commercial release. UFP MedTech’s quality team supports OEMs with full documentation through validation planning and execution.

Further detail on ISO 13485 and FDA QMSR is available directly from the relevant regulatory bodies.

From Prototype to Scalable Manufacturing: The UFP Technologies Process

UFP MedTech operates as a single-source CDMO; OEMs work with one partner from concept through commercialization, eliminating the handoff risk and timeline delays that come from separating design and manufacturing.

The process follows these stages:

• Design Consultation: UFP MedTech’s engineering team reviews the product concept, application requirements, and regulatory classification to establish a design and development roadmap.
• Material Selection: based on barrier performance requirements, sterilization method, and biocompatibility needs, UFP MedTech recommends materials from its qualified library or evaluates new materials against the specification.
• Prototype Development: initial prototypes are built in-house, enabling rapid design iteration without the delays and costs of external tooling or third-party build partners.
• Design Lock: once the design meets performance and regulatory requirements, the design is locked and transferred to manufacturing with full documentation traceability.
• Validation: process validation (IQ/OQ/PQ), sterilization validation, and packaging integrity testing are executed against the agreed protocol. UFP MedTech manages validation as a project-managed deliverable, not an afterthought.
• High-Volume Manufacturing: production scales within the same quality system, using validated processes, qualified materials, and documented controls. No re-qualification. No new supplier relationships. No regulatory exposure from the transition.

What to Look for in a CDMO Partner for Infection Prevention Applications

Selecting a CDMO partner for infection prevention device manufacturing is a high-stakes decision. Here are the criteria OEM engineers and procurement teams should use to evaluate candidates:

• ISO 13485 Certification and FDA Registration: non-negotiable. Since certification is site-specific, ask for the scope of certification and confirm which facilities are covered, not just the certificate.
• Cleanroom and CER Manufacturing Capability: verify the class level, monitoring program, and whether the environment is appropriately matched to the product type. Surgical drapes and barrier products have different environmental requirements than fluid management assemblies. Ask specifically about Controlled Environment Room (CER) capability, not just ISO class level.
• Materials Expertise: a partner with a qualified material library reduces lead time and de-risks biocompatibility and sterilization validation. Ask how materials are qualified and what the change control process looks like.
• Integrated Design Engineering: design and manufacturing under one roof eliminates the single biggest source of program delays: the handoff. If your CDMO partner cannot support design iteration, you will pay for it in timeline.
• Validation Experience: sterilization and process validation are where many programs stall. A partner with in-house validation capability and documented precedent shortens this phase significantly.
• Scalability: prototype capability is a commodity. Ask specifically how your CDMO partner manages the transition from development to commercial volumes, and what quality controls apply at scale.

Frequently Asked Questions

What infection prevention products does UFP MedTech manufacture?

UFP MedTech manufactures a range of infection prevention medical devices for OEM customers. For Surgical Site Infection (SSI) prevention: surgical robot drapes, equipment covers, and surgical prep applicators (e.g. CHG and iodine). For CLABSI prevention: disinfecting caps, IV port cleaners, and other fluid management components. For Ventilator-Associated Pneumonia (VAP): ventilator circuit components, foam-tipped oral swabs, and fluid management components. Products are designed and manufactured under a single quality system across ISO 13485 certified and FDA registered facilities, from prototype through high-volume production.

What materials are used in infection prevention medical devices?

The most commonly specified materials for infection prevention devices include open-cell foams (e.g. reticulated polyurethane), closed-cell foams (e.g. reticulated polyurethane), films, and non-wovens. Foams are often used in applicators, oral care products, disinfecting components, fluid absorption applications, cushioning, sealing, fluid resistance, and controlled compression. Films, including TPU and polyethylene, are commonly used in draping systems, equipment covers, fluid containment components, and sterile barrier packaging applications. Non-wovens are used in drapes and procedural components. Material selection is driven by the specific HAI application, biocompatibility requirements (ISO 10993), and sterilization method compatibility.

Can UFP MedTech support both prototype and high-volume manufacturing?

Yes. UFP MedTech operates as a single-source CDMO partner supporting OEMs from initial design consultation and prototype builds through validated, high-volume production. There is no handoff between development and manufacturing which eliminates re-qualification risk and accelerates time to market.

What certifications does UFP MedTech hold for infection prevention device manufacturing?

UFP MedTech has ISO 13485 certified and FDA registered facilities aligned with ISO 13485 and applicable FDA Quality Management System Regulation (QMSR / 21 CFR Part 820) requirements. Our manufacturing processes, supplier controls, and documentation are designed to support OEM regulatory submissions and audit requirements.

Partner with UFP MedTech for Infection Prevention Manufacturing

UFP MedTech combines design engineering capability, materials expertise, and regulated manufacturing under a single CDMO framework making us the partner of choice for OEMs developing and scaling infection prevention solutions. From your first design consultation through your first commercial shipment, we eliminate the handoffs, compress the timeline, and build regulatory compliance into every step.

Ready to move your infection prevention project forward? Contact UFP MedTech to start the conversation.

Related reading:

• Explore UFP MedTech’s full range of infection control solutions →
• Medical Device Development: From Concept to Commercialization →
• Medical-Grade Foam Materials →